Syngene International Limited
Nippon India Mutual Fund bought 16,00,307 shares of Syngene International for ₹69.62 Cr at ₹435.05 apiece in an open market transaction, increasing its stake from 6.72% to 7.12%.
India's first Contract Research Organization, Syngene provides integrated drug discovery, development, and manufacturing services through a single platform known as CRAMS. Established in 1993 as a Biocon subsidiary, the company operates extensive research and manufacturing facilities spanning multiple locations across the country. It serves global pharmaceutical and biotechnology clients with end-to-end solutions, from early-stage research through commercial-scale production.
India's fifth-largest AMC with over Rs 6 lakh crore in AUM, backed by Japan's Nippon Life Insurance which holds majority stake. Formerly Reliance MF, rebranded in 2019 after Nippon's acquisition. Sailesh Raj Bhan has run the equity book for over two decades and is one of India's most experienced active managers. Known for sector rotational calls and a deep research bench.